What is the purpose of this trial?
This study will evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF), including but not limited to those who are heterozygous for the F508del mutation
Ages: 12 years and older
Vertex Pharmaceuticals Incorporated
Start Date: 09/17/2018
End Date: 04/24/2021
Last Updated: 12/20/2018
Study HIC#: 2000022968